CRISPR Therapeutics AG: insider trades · United States · SEC (Form 4)

About CRISPR Therapeutics AG

CRISPR Therapeutics AG is a leading biotechnology company focused on genome editing and the development of transformative medicines for serious diseases. The company is listed on the U.S. Nasdaq market (United States) under the ticker CRSP, placing it among the most visible pure-play CRISPR names in the public markets. It was incorporated on October 31, 2013 in Switzerland, originally as Inception Genomics AG, and renamed CRISPR Therapeutics AG in 2014. Its corporate headquarters are in Zug, Switzerland, while research and development activities are anchored in the United States, particularly in Boston and San Francisco. ([crisprtx.gcs-web.com](https://crisprtx.gcs-web.com/investor-faqs?utm_source=openai)) The company’s flagship commercial asset is CASGEVY® (exagamglogene autotemcel, or exa-cel), the world’s first approved CRISPR-based therapy. Developed with Vertex, CASGEVY is a non-viral ex vivo gene-edited cell therapy for patients with severe sickle cell disease and transfusion-dependent beta thalassemia. Under the amended collaboration, Vertex leads global development, manufacturing, and commercialization, with profits and costs shared 60/40 worldwide. CASGEVY is now approved in multiple major markets, including the United States, the European Union, and Great Britain, making it the company’s key near-term commercial and strategic catalyst. ([crisprtx.gcs-web.com](https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and-0/?utm_source=openai)) Beyond CASGEVY, CRISPR Therapeutics is building a broader pipeline spanning in vivo liver editing, autoimmune disease, oncology, regenerative medicine, and cardiometabolic indications. Its LNP-based in vivo franchise includes CTX310, an ANGPTL3 program that moved into Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after encouraging Phase 1 data; CTX320 and the next-generation CTX321 for LPA; CTX460 for alpha-1 antitrypsin deficiency; and CTX340 for refractory hypertension. The company is also advancing zugo-cel, an allogeneic CAR-T candidate in autoimmune disease and hematologic malignancies, alongside a regenerative medicine program for type 1 diabetes and a siRNA collaboration with Sirius Therapeutics. ([ir.crisprtx.com](https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and-0)) From an equity-investment perspective, CRISPR Therapeutics has an important first-mover advantage in CRISPR medicine, supported by the historical approval of CASGEVY and a scientifically credible platform. At the same time, the investment case remains typical of an advanced-stage biotech: clinical and regulatory risk is still significant, commercialization is early, and ongoing funding needs remain material. Recent highlights include continued patient uptake for CASGEVY, positive Phase 1 data for CTX310, ongoing progress in zugo-cel, and a proposed $350 million convertible senior notes offering announced in March 2026 to strengthen financial flexibility and support the expanding pipeline. ([ir.crisprtx.com](https://ir.crisprtx.com/node/14691/pdf))